Citius Oncology Statistics
Total Valuation
Citius Oncology has a market cap or net worth of $88.72 million. The enterprise value is $85.22 million.
Important Dates
The last earnings date was Friday, February 13, 2026, before market open.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Citius Oncology has 88.28 million shares outstanding. The number of shares has increased by 11.84% in one year.
| Current Share Class | 88.28M |
| Shares Outstanding | 88.28M |
| Shares Change (YoY) | +11.84% |
| Shares Change (QoQ) | +11.54% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 1.51% |
| Float | 14.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.49 |
| Forward PS | 1.41 |
| PB Ratio | 1.46 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.07.
| Current Ratio | 0.83 |
| Quick Ratio | 0.25 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -84.81 |
Financial Efficiency
Return on equity (ROE) is -47.41% and return on invested capital (ROIC) is -26.07%.
| Return on Equity (ROE) | -47.41% |
| Return on Assets (ROA) | -13.96% |
| Return on Invested Capital (ROIC) | -26.07% |
| Return on Capital Employed (ROCE) | -34.29% |
| Weighted Average Cost of Capital (WACC) | 20.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.04 |
Taxes
In the past 12 months, Citius Oncology has paid $1.06 million in taxes.
| Income Tax | 1.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.92% in the last 52 weeks. The beta is 3.04, so Citius Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 3.04 |
| 52-Week Price Change | +6.92% |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 1.63 |
| Relative Strength Index (RSI) | 36.83 |
| Average Volume (20 Days) | 389,779 |
Short Selling Information
The latest short interest is 913,552, so 1.03% of the outstanding shares have been sold short.
| Short Interest | 913,552 |
| Short Previous Month | 1.21M |
| Short % of Shares Out | 1.03% |
| Short % of Float | 6.47% |
| Short Ratio (days to cover) | 4.59 |
Income Statement
In the last 12 months, Citius Oncology had revenue of $3.94 million and -$23.64 million in losses. Loss per share was -$0.31.
| Revenue | 3.94M |
| Gross Profit | 3.15M |
| Operating Income | -22.38M |
| Pretax Income | -22.58M |
| Net Income | -23.64M |
| EBITDA | n/a |
| EBIT | -22.38M |
| Loss Per Share | -$0.31 |
Full Income StatementBalance Sheet
The company has $7.30 million in cash and $3.80 million in debt, with a net cash position of $3.50 million or $0.04 per share.
| Cash & Cash Equivalents | 7.30M |
| Total Debt | 3.80M |
| Net Cash | 3.50M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 58.41M |
| Book Value Per Share | 0.69 |
| Working Capital | -7.56M |
Full Balance SheetCash Flow
| Operating Cash Flow | -12.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 79.99% |
| Operating Margin | -567.43% |
| Pretax Margin | -572.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Citius Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.84% |
| Shareholder Yield | -11.84% |
| Earnings Yield | -26.64% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Citius Oncology is $6.00, which is 497.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 497.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Citius Oncology has an Altman Z-Score of -0.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.29 |
| Piotroski F-Score | 2 |
